MDG1.DU - MEDIGENE AG NA O.N.

Dusseldorf - Dusseldorf Delayed Price. Currency in EUR
13.88
+0.81 (+6.20%)
At close: 3:26PM CET
Stock chart is not supported by your current browser
Previous Close13.07
Open13.12
Bid0.00 x 0
Ask0.00 x 0
Day's Range13.12 - 13.98
52 Week Range8.72 - 14.55
Volume573
Avg. Volume171
Market CapN/A
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • PR Newswirelast month

    Medigene Collaborates with RXi Pharmaceuticals to Further Sharpen its Therapeutic T cells

    MARLBOROUGH, Mass., Dec. 11, 2017 /PRNewswire/ -- RXi Pharmaceuticals Corporation (RXII) announced today that it has entered into a research collaboration with Medigene AG (MDG1, Frankfurt, Prime Standard, TecDAX) to explore potential synergies of using RXi's self-delivering RNAi technology (sd-rxRNA®) in combination with Medigene's recombinant TCRs to develop modified T cells with enhanced efficacy and/or safety. The preclinical research program will examine the applicability of RXi's sd-rxRNA technology to be integrated into Medigene's process to produce receptor-modified T cells with the ultimate goal to further improve Medigene's T cell therapies for the treatment of cancer patients.

  • We're sorry this is all we were able to find about this topic.